Moleculin Biotech MBRX 深 沪
等待开盘 10-07 09:30:00 美东时间
0.4555
-0.021
-4.43%
华盛通- 最 高0.899
- 今 开0.4878
- 成交量 40.54万股
- 最 低 0.45
- 昨 收 0.4766
- 总市值 1.30万
- 52周最高 15.75
- 市盈率 静 --
- 换手率 1418.65%
- 52周最低 0.2625
- 委 比 94.06%
- 总股本 2.86万
- 历史最高 21555.00
- 量 比 1.37
- 振 幅 94.21%
- 历史最低 0.3123
- 每 手 1
- 风险率 3.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why is Moleculin Stock Falling Today?
Moleculin reports interim Phase 2/3 trial data as Annamycin shows higher remission rates than control in relapsed or refractory acute myeloid leukemia
07-01 02:00
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rates in relapsed AML patients.
05-14 00:41
Dow Falls Over 250 Points; US Initial Jobless Claims Decline
U.S. stocks traded lower this morning, with the Dow Jones index falling more th...
02-19 22:45
Moleculin Biotech Secures Japan Patent Allowance For Liposomal Annamycin Method
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 titled, "METHOD OF
02-17 21:37
Moleculin Biotech Regains Nasdaq Listing Compliance; Delisting Hearing Canceled
As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which
01-07 21:38
Moleculin Announces $5.9 Million Public Offering
Moleculin Biotech announced a public offering of 16 million shares and Series E warrants to raise $5.9 million. Funds will be used to advance Annamycin and other drug pipelines through clinical development and preclinical studies. The company is currently conducting the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (AML) and expects the offering to close on June 23, 2025.
2025-06-20 13:20
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
Moleculin Biotech's Annamycin aims to eliminate cardiotoxicity in anthracycline-based cancer treatments. The FDA has approved a pediatric clinical study for children as young as 6 months, targeting relapsed/refractory acute myeloid leukemia (R/R AML). The MIRACLE trial in adults is ongoing, with initial data expected in late 2025. The pediatric trial is planned to start in late 2027.
2025-06-18 11:30
Moleculin Participates in Virtual Investor “What This Means” Segment
Moleculin Biotech announced positive topline results from its U.S. Phase 1B/2 clinical trial of Annamycin for treating Soft Tissue Sarcoma Lung Metastases (STS lung mets). The trial evaluated Annamycin's safety and efficacy as a single agent for patients with STS lung mets appropriate for chemotherapy. Brian Andrew Van Tine, MD, PhD, discussed the results in a Virtual Investor segment.
2025-06-11 13:15
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
Moleculin Biotech announces the release of a KOL webcast discussing final data from its U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. The on-demand webcast is available on the company’s website for 90 days.
2025-06-05 12:00
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Moleculin Biotech reported positive results from its Phase 1B/2 Annamycin trial for STS lung metastases, with a 59.4% clinical benefit rate. Median overall survival was 20 months, exceeding expectations for second-line monotherapies. Annamycin showed no cardiotoxicity and strong potential for addressing 13,500 annual cases, with a market opportunity of $2.6B by 2030.
2025-06-04 12:45
